These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33108587)

  • 21. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
    Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
    Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
    Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
    Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
    Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.
    Ucan A; Cerci P; Efe S; Akgun H; Ozmen A; Yagmuroglu A; Bilgin M; Avci D
    Virol J; 2021 May; 18(1):102. PubMed ID: 34034765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of favipiravir in the treatment of COVID-19.
    Joshi S; Parkar J; Ansari A; Vora A; Talwar D; Tiwaskar M; Patil S; Barkate H
    Int J Infect Dis; 2021 Jan; 102():501-508. PubMed ID: 33130203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging treatment strategies for COVID-19 infection.
    Gavriatopoulou M; Ntanasis-Stathopoulos I; Korompoki E; Fotiou D; Migkou M; Tzanninis IG; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
    Clin Exp Med; 2021 May; 21(2):167-179. PubMed ID: 33128197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
    Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
    Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
    Driouich JS; Cochin M; Lingas G; Moureau G; Touret F; Petit PR; Piorkowski G; Barthélémy K; Laprie C; Coutard B; Guedj J; de Lamballerie X; Solas C; Nougairède A
    Nat Commun; 2021 Mar; 12(1):1735. PubMed ID: 33741945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
    Manabe T; Kambayashi D; Akatsu H; Kudo K
    BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
    Lai CC; Chao CM; Hsueh PR
    J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
    Mortaz E; Bassir A; Dalil Roofchayee N; Dezfuli NK; Jamaati H; Tabarsi P; Moniri A; Rezaei M; Mehrian P; Varahram M; Marjani M; Mumby S; Adcock IM
    Int Immunopharmacol; 2021 Apr; 93():107407. PubMed ID: 33631512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.